{{Rsnum
|rsid=3219175
|Gene=RETN
|Chromosome=19
|position=7668969
|Orientation=plus
|GMAF=0.08402
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=RETN
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 2.7 | 97.3
| HCB | 2.2 | 33.6 | 64.2
| JPT | 3.5 | 35.4 | 61.1
| YRI | 2.0 | 32.0 | 66.0
| ASW | 0.0 | 21.1 | 78.9
| CHB | 2.2 | 33.6 | 64.2
| CHD | 1.9 | 31.5 | 66.7
| GIH | 0.0 | 5.9 | 94.1
| LWK | 1.8 | 15.5 | 82.7
| MEX | 0.0 | 3.6 | 96.4
| MKK | 1.3 | 17.4 | 81.3
| TSI | 0.0 | 2.0 | 98.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20300528
|Title=A at single nucleotide polymorphism-358 is required for g at -420 to confer the highest plasma resistin in the general Japanese population
|OA=1
}}

{{PMID Auto
|PMID=21275461
|Title=Relationship of resistin levels with endometrial cancer risk
}}

{{PMID Auto
|PMID=15338456
|Title=The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3.
|OA=1
}}

{{PMID Auto
|PMID=19074981
|Title=Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study.
|OA=1
}}

{{PMID Auto
|PMID=20131043
|Title=Is rs34861192 or rs1862513 a more promising variant for determining plasma resistin in an aged Japanese population?
|OA=1
}}

{{PMID Auto
|PMID=25011018
|Title=Increased Protein and mRNA Expression of Resistin After Dexamethasone Administration
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}